Live-Attenuated Respiratory Syncytial Virus Vaccine With Deletion of RNA Synthesis Regulatory Protein M2-2 and Cold Passage Mutations Is Overattenuated

Abstract Background The live respiratory syncytial virus (RSV) candidate vaccine LIDcpΔM2-2 is attenuated through deletion of M2-2 and 5 cold-passage mutations. Methods RSV-seronegative children aged 6–24 months received a single intranasal dose of 105 plaque-forming units (PFU) of LIDcpΔM2-2 or placebo. RSV serum antibodies, vaccine infectivity, and reactogenicity were assessed. Results Four of 11 (36%) vaccinees shed vaccine virus with median peak titers of 1.6 log10 PFU/mL by quantitative culture and 4.5 log10 copies/mL by polymerase chain reaction; 45% had ≥4-fold rise in serum-neutralizing antibodies. Respiratory symptoms or fever were common in vaccinees (64%) and placebo recipients (6/6, 100%). Conclusions RSV LIDcpΔM2-2 is overattenuated. Clinical Trial Numbers. NCT02890381, NCT02948127.

[1]  R. Karron,et al.  Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children , 2018, The Journal of infectious diseases.

[2]  R. Karron,et al.  Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children , 2018, The Journal of infectious diseases.

[3]  J. Vekemans,et al.  Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016 , 2017, Vaccine.

[4]  F. Polack,et al.  Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease , 2015, Clinical and Vaccine Immunology.

[5]  R. Karron,et al.  A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children , 2015, Science Translational Medicine.

[6]  R. Karron,et al.  The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. , 2007, Vaccine.

[7]  R. Karron,et al.  Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. , 2005, The Journal of infectious diseases.

[8]  A. Bermingham,et al.  The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  B. Murphy,et al.  Recombinant Respiratory Syncytial Virus (RSV) Bearing a Set of Mutations from Cold-Passaged RSV Is Attenuated in Chimpanzees , 1998, Journal of Virology.

[10]  R. Chanock,et al.  Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Hall,et al.  Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children , 1993 .

[12]  R. Chanock,et al.  Low-temperature-grown RS virus in adult volunteers. , 1968, JAMA.

[13]  M. Lucero,et al.  Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study , 2017, The Lancet.

[14]  R. Karron,et al.  Live-attenuated respiratory syncytial virus vaccines. , 2013, Current topics in microbiology and immunology.

[15]  B. Murphy,et al.  Vaccines against Human Respiratory Syncytial Virus , 2006 .